• Users Online: 493
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 141-142

A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients


1 Institute of Bioinformatics, International Technology Park, Bengaluru, Karnataka, India
2 Institute of Bioinformatics, International Technology Park, Bengaluru; Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India

Date of Submission31-Dec-2019
Date of Acceptance08-Jan-2020
Date of Web Publication24-Feb-2020

Correspondence Address:
Prashant Kumar
Faculty Scientist, Institute of Bioinformatics, Discoverer Building, International Technology Park, Whitefield, Bengaluru - 560 066, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/CRST.CRST_133_19

Get Permissions


How to cite this article:
Sambath J, Deb B, Kumar P. A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients. Cancer Res Stat Treat 2020;3:141-2

How to cite this URL:
Sambath J, Deb B, Kumar P. A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Apr 10];3:141-2. Available from: http://www.crstonline.com/text.asp?2020/3/1/141/279092



Accurate testing of genomic alterations at the time of diagnosis and at disease progression is a crucial aspect of therapeutic management for the patients. Traditionally, solid tumor tissue biopsy has been considered the gold standard for the detection of molecular alterations in many malignancies including non-small cell lung cancer (NSCLC). However, more recently, isolation and analysis of circulating tumor DNA (ctDNA) from the plasma has emerged as an effective and promising tool for the performance of molecular testing.[1] In a study by Pandey et al.,[2] the authors evaluated the outcomes of patients treated on the basis of the epidermal growth factor receptor (EGFR) status determined through liquid biopsy. They further calculated the progression-free survival and overall survival of the patients and observed their treatment based on the liquid biopsy. The findings show a comparable outcome to those of a tissue-based biopsy. The authors used droplet digital polymerase chain reaction-based peripheral blood ctDNA testing, a cost-effective, rapid, and convenient platform for targeted mutation profiling. The study and the accompanying editorial concluded that ctDNA EGFR mutation testing could be a diagnostic tool in biopsy-ineligible advanced metastatic NSCLC.[3]

The authors have used only the samples from the biopsy-ineligible patients; however, the study is based on retrospective observations and must be validated in different cohorts of patients including smokers, nonsmokers, and gender-specific lung cancer patients. The authors also did not follow up the patients over the course of treatment for secondary mutations. Incorporation of such approaches to the study would provide a broader application of the utilization of ctDNA in treatment response. However, ctDNA approach is very timely, accurate, specific, as mutations in ctDNA have been reported to be consistent with those in the tumor DNA.[4]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol 2018;13:1248-68.  Back to cited text no. 1
    
2.
Pandey A, Dutt S, Singh A, Kumar A, Singh S. Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients. Cancer Res Stat Treat 2019;2:197-203.  Back to cited text no. 2
  [Full text]  
3.
Choughule A, D'Souza H. Liquid biopsy in lung cancer-hope or hype? Cancer Res Stat Treat 2019;2:221-3.  Back to cited text no. 3
  [Full text]  
4.
Li H, Jing C, Wu J, Ni J, Sha H, Xu X, et al. Circulating tumor DNA detection: A potential tool for colorectal cancer management. Oncol Lett 2019;17:1409-16.  Back to cited text no. 4
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed100    
    Printed0    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal